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Abstract 
 
 
 
 
 
 
 
There is conflicting evidence regarding the effect of AT1 receptor antagonists on 
learning and memory processes. The effects of angiotensin II and losartan administration 
into CA1 hippocampal area on the avoidance performance in olfactory bulbectomized 
(OBX) rats using active avoidance (shuttle box) test and passive avoidance (step through) 
test were investigated. Rats were microinjected unilaterally through implanted guide 
cannulas into the CA1 area of the dorsal hippocampus and the drugs were administered 
separately, 5 minutes before each training session. The microinjections of losartan into the 
left, but not the right CA1 hippocampal area improved the acquisition and retention of 
active and passive avoidance learning, thus suggesting dependence on the side of injection. 
The unilateral (left or right) administration of angiotensin II did not significantly affect the 
performance of OBX rats in the avoidance tasks. A differential distribution of the AT1 
receptors in the left and right hemisphere could contribute for the asymmetry in the 
behavioral effects of the AT receptor antagonist. 
 
  
Keywords: angiotensin II, losartan, learning, memory, asymmetry, hippocampus, 
olfactory bulbectomy 
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Introduction 
The octapeptide angiotensin II (Ang II) is a 
potent effector hormone of the renin-angiotensin 
system (RAS). The brain has its own intrinsic RAS 
and most of its components are expressed in the 
central nervous system. The brain RAS includes 
the biologically active angiotensin peptides: Ang 
II, Ang III, Ang IV and Ang-(1-7) (1). Four 
receptor types have been proposed within the RAS: 
the Ang II type 1 and 2 receptors (AT1, AT2), Ang 
IV-specific receptor(AT4), and Ang-(1–7) 
selective receptor (2- 4). The AT1 and AT2 types 
are structurally similar, G-protein coupled 
receptors. The AT4 receptor is a protein, which is 
not G-protein-linked, while Ang-(1–7) exerts its 
actions via the G protein-coupled Mas receptor. 
The hippocampus is a part of the limbic 
system, which is important for cognitive processes. 
Both the concentration of Ang II and the 
expression of angiotensin receptors are particularly 
high in the hippocampus and the CA1 hippocampal 
neurons are reported to be sensitive to Ang II (5, 
6). Ang II being a part of the brain RAS, acts as a 
neurotransmitter or a neuromodulator. Increasing 
evidence supports the involvement of Ang II and 
its receptors in learning and memory processes, 
although the behavioral consequences apparently 
depend upon the methods, doses and location of 
the treatment (7-9). Previous studies have found 
behavioral asymmetries (in locomotor activity, 
anxiety, learning and memory) following 
microinjections of Ang II into the CA1 
hippocampal area (9- 11). 
The role of Ang II in brain pathology is 
poorly understood and not widely studied. Ang II 
has been suggested to participate in the 
pathophysiology of stress, Alzheimer's disease and 
depression. The first evidence that brain RAS may 
be involved in depressive disorder was observed in 
hypertensive patients undergoing captopril 
treatment (12). Investigations demonstrated that 
high angiotensin-converting enzyme activity led to 
high Ang II formation, which was associated with 
depression, hypothalamic-pituitary axis 
hyperactivity and anxiety (13-15). It was found 
that the blockage of angiotensin II synthesis with 
angiotensin-converting enzyme inhibitors (ACEI) 
in transgenic rats with high production of brain 
Ang II reduces the increased anxiety (16, 17). 
There is increasing evidence indicating beneficial 
effects of angiotensin II receptor blockers (ARBs) 
in brain disorders such as stroke, Alzheimer's 
disease, depression and stress (18). In an 
experimental study, the AT1 antagonist losartan 
improved depression-like behavior in mice, as 
determined by the forced swim test (19). Clinical 
research demonstrated that the treatment with 
ARBs decreases anxiety and depression in patients 
(20, 21). The ACEI led to similar therapeutic 
effects - improved the efficacy of antidepressants 
and decreased anxiety and depression in 
normotensive rats (22, 23).  
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Olfactory bulbectomy (OBX) provides a 
well-validated animal model of depression. It is 
considered most suitable for studying the 
neurochemical mechanisms underlying the 
pathophysiology of depression. Bilateral removal 
of the olfactory bulbs in rats induces a syndrome of 
behavioral deficits that reflect a disruption of 
cortical and limbic regions, accompanied by 
neurochemical, endocrine and immune alterations, 
reminiscent of symptoms of human depression (24, 
25). OBX leads to extensive cognitive 
impairments, with deficits in learning and memory 
(24, 26, 27). Borre et al. and Douma et al. have 
suggested that OBX in rats can serve also as an 
animal model of neurodegeneration (28, 29). 
According to Yehuda and Rabinovitz, OBX 
mimics a complex of Alzheimer’s symptoms, 
including cognitive decline, increased locomotor 
activity, decreased food intake, etc. (30). The 
neurodegeneration of the septo-hippocampal 
cholinergic pathways (31), which accompany 
memory impairments and the elevation of amyloid 
beta level in the brain (32) also point to the 
usefulness of OBX as an animal model of 
Alzheimer’s disease. 
Bearing in mind the above considerations, the 
aim of our study was to examine the effects of Ang 
II and the AT1 receptor antagonist losartan on 
learning and memory processes after unilateral 
application into CA1 hippocampal area in OBX 
rats. 
 
Materials and methods 
Animals 
Male Wistar rats (200 – 220 g, 2 month old at 
the time of surgery) were housed individually in 
polypropylene boxes with free access to food and 
water. The animals were maintained in a constant 
temperature environment (22 ± 2°C) on a 12h 
light/dark cycle (lights on at 6.00 am). The 
behavior experiments were carried out between 
10:00 am and 1:00 pm. After the testing procedure, 
the rats were returned to their respective home 
cages. 
The experiments were performed according 
to the “Rules for care and experiments on 
laboratory animals” of the Ethics Committee of the 
Institute of Neurobiology, Bulgarian Academy of 
Sciences. All efforts were made to minimize 
animal suffering and reduce the number of animals 
used in the study. 
Surgical procedures 
Bilateral olfactory bulbectomy was carried 
out according to the method described by Kelly et 
al. (24). Seven days after bilateral olfactory 
bulbectomy a cannula was surgically implanted 
into the CA1 hippocampal area as described 
previously (9). 
Behavioral methods 
The animals were tested in a two-way active 
avoidance test (shuttle box) and a passive 
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avoidance test (step-through) as described 
previously (7). 
Statistical analysis 
Separate two-factor analysis of variance 
(ANOVA) was used to analyze the data obtained 
for the number of avoidances (shuttle-box) in the 
learning test (1st and 2nd training day) and the 
memory test (24 h after the 2nd training day) 
between subject factors: drug (three levels: Ang II, 
losartan or saline) and side of injection (two levels: 
left and right). ANOVA data were analyzed further 
by post-hoc Student-Newman–Keuls (SNK). 
Analysis of the passive avoidance data was 
performed using χ2 tests. 
Results 
Shuttle box test 
The bilateral removal of the olfactory bulbs 
resulted in an impairment of the learning and 
memory in the active avoidance task (shuttle 
box).The number of avoidances of rats with 
developed depression was significantly lower as 
compared to the sham-operated controls on the 1st 
training day (P  0.001), 2nd training day (P  
0.001) and on the retention test (P  0.001) (Fig. 
1A, B, C).Two way ANOVA demonstrated 
significant effects for the factors “drug” (Ang II 
and losartan) on the number of avoidances (F2,35= 
13,819, P<0.001)and “side” of injection (F1,35= 
8.533, P≤ 0.04) on the 1sttraining day. There was 
also significant interaction between “drug”×“side” 
of injection (F2, 35=8,402, P≤0.001). On the 
2ndtraining day ANOVA demonstrated significant 
effects for the factors “drug“ (F2,35 = 32,439, P ≤ 
0.001), “side“ (F1,35 = 19.756, P ≤ 0.001) and a 
significant interaction between the factors “drug”× 
“side “ (F1,35 = 18.756, P ≤ 0.001). At the retention 
test ANOVA revealed a significance for “drug“ 
(F2,35 = 25.833, P ≤ 0.001), side of injection (F1,35 
= 15,873, P ≤ 0.001) and a significant interaction 
between “drug” × “side” (F2,35 = 18,373; P ≤ 
0.001). 
Post-hoc SNK comparisons demonstrated 
that losartan infused into CA1 area produced 
significantly greater number of avoidances when 
injected into the left CA1 area on 1st day 
(P  0.001), 2nd day (P  0.001) and at the 
retention test (P  0.001), as compared to the 
respective saline-treated OBX-controls (Fig. 1A, 
B, C). Microinjected into the right side, losartan 
did not affect significantly the number of 
avoidances on the training days and at the retention 
test (Fig. 1A, B, C).Upon left-side or right-side 
administration, Ang II did not significantly affect 
the number of avoidances, as compared to the 
respective OBX saline-treated controls during the 
whole experimental period(Fig. 1A, B, C). 
The unilateral injection of losartan showed a 
clear lateralized improvement of learning and 
memory. Microinjected into the left CA1 area 
losartan increased significantly the number of 
avoidances as compared to the right-side 
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injections: on the 1sttraining day (P ≤ 0.001), on 
the 2ndday (P ≤ 0.001) and at the retention test(P ≤ 
0.001) (Fig. 1A, B, C). 
Step through test  
One way ANOVA on the latent time of OBX 
rats showed a significant effect on the retention 
tests: on the 3rd h after training (F1,11 = 155,702; 
P ≤ 0.001) and on the 24th after training (F1,11 
= 218,256; P ≤ 0.001). At the passive avoidance 
task, bulbectomized rats demonstrated a significant 
decrease of the latent time on the retention tests: on 
the 3rd h (P ≤ 0.001) and on the 24th (P ≤ 0.001) as 
compared to the sham-OBX group. The number of 
OBX rats fulfilling the learning criteria diminished 
to 0%,as compared to the sham operated controls 
which reached50%learning criteria on the 3rdh and 
63% on the 24th h (Fig. 1A, B). Separate two way 
ANOVA demonstrated significant effects of the 
factors “drug”(F2,47 = 45,014; P ≤ 0.001) and 
“side”(F1,47= 42,103, P≤ 0.04)for the 3rdhThere 
was also significant interaction between 
“drug”×“side” of injection (F2,47=34,715, 
P≤0.001). At the retention test ANOVA showed 
significance for “drug“ (F2,47 =150,410, P ≤ 0.001), 
“side “ (F1,47 = 115,394, P ≤ 0.001), as well as a 
significant interaction between “drug” × “side” 
(F2,47 = 118,530; P ≤ 0.001). 
Post hoc test showed that the microinjection 
of losartan into the left CA1 area prolonged the 
latency time on the 3rdh (P ≤ 0.001) and on the 24th 
h (P ≤ 0.001) and increased the percentage of the 
rats that reached the learning criteria on the 3rdh 
(50%)and on the 24th h(63%).Losartan infused into 
the right side did not affect the performance of the 
OBX rats in the step-through task (Fig. 2A, B).The 
injection of losartan into the left CA1 area 
increased significantly the latent time on the 3rdh 
(P ≤ 0.001) and 24th h (P ≤ 0.001) as compared to 
the right-side infusions (Fig. 2A, B). The effect of 
Ang II administered unilaterally (left- or right side) 
did not differ significantly from the respective 
saline treated OBX controls (Fig. 2A, B). 
Discussion 
The bilateral olfactory bulbectomy markedly 
impaired the performance of rats in both avoidance 
tasks compared to the sham-operated controls, as 
has been reported previously (24, 27). Our results 
showed a lateralized ameliorating effect of the 
AT1 receptor antagonist losartan on learning and 
memory deficits in OBX rats. The microinjections 
of losartan into the left but not the right CA1 
hippocampal area improved the acquisition and 
retention of active and passive avoidance learning, 
thus suggesting dependence on the side of 
injection. In addition, the unilateral (left or right) 
administration of angiotensin II did not affect 
significantly the performance of OBX rats in the 
avoidance tasks. 
Studies have shown controversial results 
about the effects centrally administered AngII on 
learning and memory processes. In the avoidance 
paradigms, used to evaluate learning and memory 
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of rodents, it has been observed that 
intracerebroventricular (i.c.v.) injection of Ang II 
impairs (34), improves (35-37), or has no effect 
(38) on the cognitive performance. The 
administration of Ang II into CA1 hippocampal 
area in a step-down inhibitory avoidance task 
produced a dose-dependent amnesic effect, which 
was blocked by the AT2 receptor antagonist, PD 
123319, but not by the AT1 receptor antagonist 
losartan (39, 40). The conflicting results about the 
cognitive effects of Ang II can be explained by the 
fact that these effects are very sensitive to the 
different methodological approaches (time interval 
between the injection of Ang II and the performing 
of the test, type of administration, differences in 
dosage, duration of treatment, number of training 
sessions, and type of memory task evaluated). 
 Concerning the type of receptors involved in 
the effects of Ang II on cognitive processes, data 
are contradictory too. Braszko reported that both 
AT1 and AT2 receptors may contribute to the 
effects of Ang II in passive avoidance, object 
recognition and active avoidance tests, with an 
exception of lack of influence of AT1 receptor 
inhibition on active avoidance acquisition (41), 
while other authors (37, 42) observed no effect of 
centrally applied losartan on active avoidance tests.  
By comparing the effect of captopril (ACEI) 
and losartan (a selective AT1 receptor antagonist) 
in an active avoidance task, Raghavendra et al. 
found that both drugs were equally effective in 
enhancing retention of memory when administered 
prior to training. Hence, it was concluded that the 
decrease in endogenous Ang II activity in the brain 
might result in improved cognitive performance 
(43). 
There are many reports about the beneficial 
effects of AT1 blockers in different experimental 
models of learning and memory impairments. 
DeNoble et al. showed that the impaired 
performance on a passive avoidance task in rats 
treated i.c.v. with renin could be offset with ACEI 
treatment, or by the application of the AT1 
receptor antagonists (44). Orally administered 
telmisartan (AT1 receptor blocker) improved 
spatial learning and memory in a type 1 diabetic 
mouse model, streptozotocin-induced diabetic 
mice (45), while pretreatment with a non-
hypotensive dose of telmisartan significantly 
inhibited cognitive decline in an experimental 
model of Alzheimer disease (46). Inaba et al. 
demonstrated that olmesartan (another AT1 
blocker) diminished the cognitive alterations 
observed ina shuttle-box avoidance task for the 
human renin and human angiotensinogen gene 
chimeric transgenic mice and suggested that 
continuous activation of the brain RAS impairs 
cognitive function via stimulation of AT1 receptor 
(47). Clinical data with Ang II antagonists tend to 
support experimental findings. It has been shown 
that losartan improves cognitive functions in 
hypertensive patients as well as in normotensive 
adults (48, 49). 
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Our results showed no effects of Ang II on 
the avoidance behavior of OBX rats. Previously, 
using the same experimental protocol, Belcheva et 
al. reported that Ang II infused into CA1 area 
enhanced acquisition and retention in a two-way 
active avoidance test (9). The bilateral removal of 
the olfactory bulbs results in neurodegeneration in 
the projection areas of the bulbs such as cortex, 
amygdala and hippocampus (25). Although data 
are lacking about the expression of RAS 
components in the brain of OBX rats, the 
neurodegenerative changes might be accompanied 
with abnormalities in RAS in different brain 
regions, similarly to the observed alterations on 
AT receptors in patients with neurodegenerative 
disorders (50, 51). It could be suggested that the 
neurodegenerative changes in the hippocampus 
and the following compensatory neuronal 
reorganization could explain the lack of effects of 
angiotensin II on the performance of OBX rats. 
The improvement of memory deficits after 
injection of losartan into CA1 area in OBX rats 
may be related to its neuroprotective, anti-
inflammatory and anti-oxidant effects. 
Neurodegenerative changes, inflammation and 
oxidative stress were found to play role in the 
etiology of OBX-induced depression. Increased 
production of oxygen reactive species, saturation 
of antioxidant enzymes, lipid peroxidation and  
generation of pro-inflammatory cytokines in the 
brain of OBX rats have been reported (52- 55). 
Angiotensin II type 1 (AT1) receptor 
blockers have shown powerful neuroprotective 
effects in vivo (56, 57). The latest research 
provided evidence that ARBs may protect the brain 
from different types of injury resulting in 
parenchyma inflammation and neuronal damage. 
Beneficial effects on memory functions for the 
AT1 receptor blockers have been demonstrated in 
traumatic animal models. For example, 
candesartan treatment reduced the lesion volume 
after controlled cortical impact injury on mice and 
improved performance in the Morris water maze 4 
weeks after injury (58). The AT1 blockers 
candesartan and telmisartan exhibited 
neuroprotective and anti-inflammatory effects in 
different models of brain injury in rodents (58- 61). 
The systemic administration of candesartan 
decreased the acute brain inflammatory response to 
a bacterial endotoxin lipopolysaccharide and 
reduced the inflammatory reaction by decreasing 
the production of cytokines and other 
inflammatory factors in the brain cortex (62, 63). 
The anti-inflammatory effects were widespread, 
occurring in many limbic areas such as 
hypothalamus, prefrontal cortex, hippocampus, and 
amygdala. 
Left–right asymmetries of brain and behavior 
are widespread among both vertebrates and 
invertebrates. Knowledge of the bilateral 
distribution of a system in brain is important to 
appropriately understand how it functions in health 
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and pathology. Data have accumulated concerning 
anatomical, functional and neurochemical 
asymmetries in the rat brain. The research on the 
impact of hippocampal left–right asymmetry on 
higher-order brain functions using “split-brain” 
mice have shown that the usage of the right 
hippocampus improves the accuracy of spatial 
memory, while performance of other 
hippocampus-dependent tasks (fear conditioning) 
was not influenced by the laterality of the 
hippocampus (64). Recently, a dissociation of 
hippocampal long-term memory function between 
hemispheres has been reported, suggesting that 
memory is routed via distinct left–right pathways 
within the mouse hippocampus (65).  
Other evidence regarding the lateralization in 
the expression of different components of RAS has 
been provided by the research of Wu et al., who 
found asymmetrical distribution of angiotensinase 
activity in the amygdala, hippocampus and 
prefrontal cortex of the rat (66). The 
aminopeptidases (APs) termed angiotensinases are 
involved in the metabolism of angiotensin 
peptides. In the hippocampus, there was a left 
predominance for AlaAP, CysAP and AspAP 
activities, while GluAP predominated in the right 
hippocampus (66, 67). It was also suggested that 
the asymmetric activity of angiotensinases in the 
rat hippocampus might be associated with both the 
direction and the intensity of behavioral 
lateralization as expressed by paw preference (66). 
Our results are in line with the reports about 
asymmetry in the effects of drugs acting on 
angiotensin receptors. Belchevaet al. observed 
lateralization in the effects of angiotensin II, 
injected into the CA1 area of rats, where left-side 
administration enhanced acquisition and retention 
in an active avoidance task (9). Previous research 
of our laboratory also demonstrated lateralized 
memory enhancing effects of Ang IV and Ang II 
after pretreatment with losartan in the CA1 area (7, 
68). 
Based on the above-mentioned findings, we 
suggest that the lateralized ameliorative effect of 
losartan on learning and memory in OBX rats 
could be attributed to a hemispheric asymmetry in 
the components of the hippocampal RAS, 
including the expression and/or activity of 
different peptides, enzymes and receptors. 
In conclusion, our study demonstrated 
lateralized beneficial effects of losartan, injected 
into the CA1 hippocampal area, on learning and 
memory deficits induced by the olfactory 
bulbectomy in rats. Ang II did not affect the 
behavior of OBX rats tested in the avoidance 
paradigms. A differential distribution of the AT1 
receptors in the left and right hemisphere could 
contribute for the asymmetry in the behavioral 
effects of the AT receptor antagonist. 
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Figure captions  
Fig. 1 (A, B, C). Effects ofAng II (0,5 μg) and 
losartan (100 μg) microinjected unilaterally into the left 
or right CA1 hippocampal area of OBX rats on the 
number of avoidances (shuttle box). A) 1sttraining day; 
B) 2ndtraining day; C) retention test. Asteriscsdepict 
comparisons of the number of avoidances, following 
injections of the drug vs respective saline injections 
into CA1 area, ***P0.001; circles depict comparisons 
of the number of avoidances, following injections into 
the left vs right-side. n=6. Means (± S.E.M.) are 
presented. 
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Fig. 2 (A, B). Effects of Ang II (0,5μg) and losartan 
(100 μg )microinjectedunilaterally into the left or right 
CA1 hippocampal area ofOBX rats on the latent time 
(step through). A) 3rd hour. B) 24th hour.***P0.001; 
Asteriscsdepict comparisons of the latent time (sec) 
following injections of the drugs vs respective saline 
injections intoCA1areas; circles depict comparisons of 
the latent time (sec), following injections into the left vs 
right-side. n=8. Means (± S.E.M.) are presented. 
 
 
 
 
 
 
 
